Trials / Completed
CompletedNCT02734433
Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors
A Phase 1 Study of Single Agent Pexidartinib in Asian Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Daiichi Sankyo Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I, non-randomized, open-label, multiple dose study of pexidartinib in Asian subjects with advanced solid tumors. The study will be conducted in a dose escalation to assess the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and preliminary antitumor activity of pexidartinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pexidartinib |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-06-13
- Completion
- 2021-05-28
- First posted
- 2016-04-12
- Last updated
- 2022-04-25
- Results posted
- 2020-04-24
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT02734433. Inclusion in this directory is not an endorsement.